CLSD Clearside Biomedical Inc

Price (delayed)

$2.38

Market cap

$136.67M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.39

Enterprise value

$121.1M

Sector: Healthcare
Industry: Biotechnology

Highlights

CLSD's debt has dropped by 69% year-on-year and by 3.4% since the previous quarter
The EPS has surged by 52% year-on-year but it has declined by 26% since the previous quarter
The company's net income rose by 41% YoY but it fell by 28% QoQ
The revenue has contracted by 20% from the previous quarter
The company's gross profit fell by 20% QoQ

Key stats

What are the main financial stats of CLSD
Market
Shares outstanding
57.42M
Market cap
$136.67M
Enterprise value
$121.1M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
13.13
Price to sales (P/S)
14.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.34
Earnings
Revenue
$7.89M
EBIT
-$18.21M
EBITDA
-$18.03M
Free cash flow
-$13.18M
Per share
EPS
-$0.39
Free cash flow per share
-$0.28
Book value per share
$0.18
Revenue per share
$0.17
TBVPS
$0.42
Balance sheet
Total assets
$19.32M
Total liabilities
$10.56M
Debt
$1.98M
Equity
$8.76M
Working capital
$8.18M
Liquidity
Debt to equity
0.23
Current ratio
1.82
Quick ratio
1.76
Net debt/EBITDA
0.86
Margins
EBITDA margin
-228.4%
Gross margin
100%
Net margin
-230.7%
Operating margin
-227.2%
Efficiency
Return on assets
-91.6%
Return on equity
-210.4%
Return on invested capital
N/A
Return on capital employed
-194.2%
Return on sales
-230.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CLSD stock price

How has the Clearside Biomedical stock price performed over time
Intraday
2.59%
1 week
-12.5%
1 month
-10.86%
1 year
11.74%
YTD
-13.14%
QTD
-3.64%

Financial performance

How have Clearside Biomedical's revenue and profit performed over time
Revenue
$7.89M
Gross profit
$7.89M
Operating income
-$17.94M
Net income
-$18.21M
Gross margin
100%
Net margin
-230.7%
The operating margin has soared by 84% YoY but it has plunged by 63% from the previous quarter
CLSD's net margin has surged by 84% year-on-year but it has dropped by 60% since the previous quarter
The company's net income rose by 41% YoY but it fell by 28% QoQ
The operating income has grown by 41% YoY but it has contracted by 31% from the previous quarter

Growth

What is Clearside Biomedical's growth rate over time

Valuation

What is Clearside Biomedical stock price valuation
P/E
N/A
P/B
13.13
P/S
14.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.34
The EPS has surged by 52% year-on-year but it has declined by 26% since the previous quarter
The price to book (P/B) is 117% higher than the 5-year quarterly average of 5.9 and 20% higher than the last 4 quarters average of 10.7
CLSD's equity is down by 21% year-on-year but it is up by 8% since the previous quarter
The P/S is 99% below the 5-year quarterly average of 1347.1 but 12% above the last 4 quarters average of 12.2
The revenue has contracted by 20% from the previous quarter

Efficiency

How efficient is Clearside Biomedical business performance
The return on sales has surged by 84% year-on-year but it has dropped by 60% since the previous quarter
The company's return on assets fell by 40% QoQ but it rose by 11% YoY
The return on equity has declined by 37% since the previous quarter but it has grown by 15% year-on-year

Dividends

What is CLSD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CLSD.

Financial health

How did Clearside Biomedical financials performed over time
The company's total assets is 83% higher than its total liabilities
The total liabilities is down by 32% YoY but it is up by 14% from the previous quarter
The company's total assets fell by 28% YoY but it rose by 11% QoQ
CLSD's debt is 77% smaller than its equity
CLSD's debt has dropped by 69% year-on-year and by 3.4% since the previous quarter
The debt to equity has plunged by 60% YoY and by 8% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.